High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results.

Moham Ed El KassasMohamed AlboraieHeba OmarYasmeen Abd El LatifMohammed Abd AlgaberAdel El TahanHesham El HalwagyShimaa AfifyMagdy ElserafyKadry ElsaeedWahid Doss

Published in: Journal of medical virology (2019)

OBV/rPTV/RBV (±SOF) is a highly effective therapy for chronic HCV patients in real life settings.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
human immunodeficiency virus
patient reported outcomes
liver fibrosis
combination therapy